For example, although VHL is primarily inactivated by somatic mutations (promoter methylation occurs in ~15% of sporadic cRCC), inactivation of the RASSF1A TSG in RCC (and in other tumour types) most commonly results from promoter methylation, whilst intragenic mutations are rare. The gene discussed is VHL; the disease is neoplasm.